{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:13:12Z","timestamp":1761844392044,"version":"3.40.4"},"reference-count":63,"publisher":"Portland Press Ltd.","issue":"1","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:p>Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the median overall survival (OS) benefit is only ~3 months, and sufficient biomarkers predicting treatment response are not available. The aim of the present study was to evaluate miRNA expression patterns from HCC tissue biopsies as potential biomarkers in patients under sorafenib treatment. Nineteen patients with advanced HCC treated with sorafenib were included. RNA was extracted from formalin-fixed paraffin-embedded (FFPE) liver biopsies. miRNA expression profiling of 818 mature miRNAs was performed using GeneChip\u00ae miRNA Array 2.0 (Affymetrix). Global miRNA patterns were assessed using unsupervised hierarchical clustering analysis (UCA), and specific miRNAs with correlation with disease control rate (DCR) or good OS were evaluated by pairwise supervised analyses. UCA divided the patients into three distinct groups by their miRNA expression patterns. However, DCR or OS did not correlate with these sub-groups. We have identified several miRNAs that correlated with either DCR or OS (P&amp;lt;0.05). However, with correction for multiple testing, these results did not reach statistical significance in this small cohort. Global miRNA analysis from very low input RNA deriving from liver biopsies showed distinctive clustering of molecular sub-groups in patients with intermediate and advanced HCC. Clinical response including OS under sorafenib did not correlate with global miRNA expression patterns, but we have identified candidate miRNAs for the prediction of DCR and OS to be evaluated in prospective studies and larger patient cohorts.<\/jats:p>","DOI":"10.1042\/cs20140007","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T08:26:28Z","timestamp":1403684788000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib"],"prefix":"10.1042","volume":"128","author":[{"given":"Jan","family":"Peveling-Oberhag","sequence":"first","affiliation":[{"name":"Medizinische Klinik 1, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"D\u00f6ring","sequence":"additional","affiliation":[{"name":"Senckenbergisches Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Senckenbergisches Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Filmann","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Biostatistik und Mathematische Modellierung, Fachbereich Medizin, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Mertens","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 1, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Piiper","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 1, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Biostatistik und Mathematische Modellierung, Fachbereich Medizin, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin-Leo","family":"Hansmann","sequence":"additional","affiliation":[{"name":"Senckenbergisches Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 1, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Trojan","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 1, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin-Walter","family":"Welker","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 1, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2014,8,27]]},"reference":[{"key":"2021113010340735500_B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"2021113010340735500_B2","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/hep.23485","article-title":"A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma","volume":"51","author":"Cabibbo","year":"2010","journal-title":"Hepatology"},{"key":"2021113010340735500_B3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"2021113010340735500_B4","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"2021113010340735500_B5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJM199903113401001","article-title":"Rising incidence of hepatocellular carcinoma in the United States","volume":"340","author":"El Serag","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"2021113010340735500_B6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.hepres.2005.11.007","article-title":"Increasing hepatitis C virus-associated hepatocellular carcinoma mortality and aging: long term trends in Japan","volume":"34","author":"Taura","year":"2006","journal-title":"Hepatol. Res."},{"key":"2021113010340735500_B7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"2021113010340735500_B8","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"2021113010340735500_B9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"2021113010340735500_B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/hep.21966","article-title":"Diagnosis of hepatic nodules 20\u00a0mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma","volume":"47","author":"Forner","year":"2008","journal-title":"Hepatology"},{"key":"2021113010340735500_B11","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"2021113010340735500_B12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021113010340735500_B13","first-page":"3075","article-title":"Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives","volume":"17","author":"Welker","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"2021113010340735500_B14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2021113010340735500_B15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"2021113010340735500_B16","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3748\/wjg.v17.i19.2450","article-title":"Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib","volume":"17","author":"Abbadessa","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"2021113010340735500_B17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3892\/ol.2013.1131","article-title":"Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma","volume":"5","author":"Gerardi","year":"2013","journal-title":"Oncol. Lett."},{"key":"2021113010340735500_B18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/MCG.0b013e31818ddfc6","article-title":"Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis","volume":"43","author":"Worns","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"2021113010340735500_B19","first-page":"86","article-title":"Use of sorafenib in advanced hepatocellular carcinoma\u2013a case study of a German Liver Center","volume":"33","author":"Welker","year":"2010","journal-title":"Onkologie"},{"key":"2021113010340735500_B20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jhep.2012.02.016","article-title":"Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma","volume":"57","author":"Personeni","year":"2012","journal-title":"J. Hepatol."},{"key":"2021113010340735500_B21","first-page":"843","article-title":"MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs","volume":"13","author":"Nana-Sinkam","year":"2010","journal-title":"IDrugs"},{"key":"2021113010340735500_B22","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1261\/rna.1534709","article-title":"Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell","volume":"15","author":"Sotiropoulou","year":"2009","journal-title":"RNA"},{"key":"2021113010340735500_B23","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1053\/j.gastro.2011.02.009","article-title":"MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a","volume":"140","author":"Toffanin","year":"2011","journal-title":"Gastroenterology"},{"key":"2021113010340735500_B24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1148\/radiol.2282021787","article-title":"Image-guided tumor ablation: proposal for standardization of terms and reporting criteria","volume":"228","author":"Goldberg","year":"2003","journal-title":"Radiology"},{"key":"2021113010340735500_B25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nar\/27.1.29","article-title":"KEGG: Kyoto encyclopedia of genes and genomes","volume":"27","author":"Ogata","year":"1999","journal-title":"Nucleic Acids Res."},{"key":"2021113010340735500_B26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J.R. Statist. Soc. B"},{"key":"2021113010340735500_B27","doi-asserted-by":"publisher","first-page":"W498","DOI":"10.1093\/nar\/gks494","article-title":"DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways","volume":"40","author":"Vlachos","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"2021113010340735500_B28","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1053\/j.gastro.2011.02.006","article-title":"Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma","volume":"140","author":"Villanueva","year":"2011","journal-title":"Gastroenterology"},{"key":"2021113010340735500_B29","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2217\/14622416.8.8.997","article-title":"Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies","volume":"8","author":"Zucnan-Rossi","year":"2007","journal-title":"Pharmacogenomics"},{"key":"2021113010340735500_B30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"2021113010340735500_B31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1053\/j.gastro.2010.10.006","article-title":"The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2","volume":"140","author":"Wong","year":"2011","journal-title":"Gastroenterology"},{"key":"2021113010340735500_B32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/hep.23380","article-title":"Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma","volume":"51","author":"Xiong","year":"2010","journal-title":"Hepatology"},{"key":"2021113010340735500_B33","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-12-2728","article-title":"Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma","volume":"19","author":"Wei","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2021113010340735500_B34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/hep.26369","article-title":"MicroRNA-216a\/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer","volume":"58","author":"Xia","year":"2013","journal-title":"Hepatology"},{"key":"2021113010340735500_B35","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1093\/carcin\/bgt160","article-title":"MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression","volume":"34","author":"Zhu","year":"2013","journal-title":"Carcinogenesis"},{"key":"2021113010340735500_B36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2011.01.001","article-title":"Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a\/b-3p as therapeutic target for hepatocellular carcinoma","volume":"19","author":"Hou","year":"2011","journal-title":"Cancer Cell"},{"key":"2021113010340735500_B37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1158\/1078-0432.CCR-07-0523","article-title":"Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival","volume":"14","author":"Jiang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2021113010340735500_B38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2353\/ajpath.2008.080096","article-title":"Elevated expression of the miR-17-92 polycistron and miR-21\u00a0in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype","volume":"173","author":"Connolly","year":"2008","journal-title":"Am. J. Pathol."},{"key":"2021113010340735500_B39","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1158\/0008-5472.CAN-06-4607","article-title":"Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma","volume":"67","author":"Gramantieri","year":"2007","journal-title":"Cancer Res."},{"key":"2021113010340735500_B40","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.1872-034X.2009.00502.x","article-title":"Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated","volume":"39","author":"Huang","year":"2009","journal-title":"Hepatol. Res."},{"key":"2021113010340735500_B41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J. Hepatol."},{"key":"2021113010340735500_B42","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1038\/sj.onc.1209283","article-title":"Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues","volume":"25","author":"Murakami","year":"2006","journal-title":"Oncogene"},{"key":"2021113010340735500_B43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2353\/jmoldx.2008.070153","article-title":"Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues","volume":"10","author":"Doleshal","year":"2008","journal-title":"J. Mol. Diagn."},{"key":"2021113010340735500_B44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-1-61779-055-3","article-title":"MicroRNA isolation from formalin-fixed, paraffin-embedded tissues","volume":"724","author":"Liu","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"2021113010340735500_B45","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3851\/IMP2401","article-title":"Plasma microRNA profile as a predictor of early virological response to interferon treatment in chronic hepatitis B patients","volume":"17","author":"Zhang","year":"2012","journal-title":"Antivir. Ther."},{"key":"2021113010340735500_B46","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1158\/0008-5472.CAN-06-4607","article-title":"Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma","volume":"67","author":"Gramantieri","year":"2007","journal-title":"Cancer Res."},{"key":"2021113010340735500_B47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ijc.25336","article-title":"Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A)","volume":"128","author":"Lan","year":"2011","journal-title":"Int. J. Cancer"},{"key":"2021113010340735500_B48","doi-asserted-by":"publisher","first-page":"e56824","DOI":"10.1371\/journal.pone.0056824","article-title":"miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7\u00a0in melanoma","volume":"8","author":"Felli","year":"2013","journal-title":"PloS One"},{"key":"2021113010340735500_B49","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","article-title":"Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model","volume":"137","author":"Kota","year":"2009","journal-title":"Cell"},{"key":"2021113010340735500_B50","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1038\/onc.2011.193","article-title":"microRNA-29 can regulate expression of the long non-coding RNA gene MEG3\u00a0in hepatocellular cancer","volume":"30","author":"Braconi","year":"2011","journal-title":"Oncogene"},{"key":"2021113010340735500_B51","doi-asserted-by":"publisher","first-page":"36677","DOI":"10.1074\/jbc.M111.270561","article-title":"MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma","volume":"286","author":"Li","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2021113010340735500_B52","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1038\/onc.2011.631","article-title":"Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression","volume":"31","author":"Petrelli","year":"2012","journal-title":"Oncogene"},{"key":"2021113010340735500_B53","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1053\/jhep.2001.28457","article-title":"Transforming growth factor beta and the liver","volume":"34","author":"Bissell","year":"2001","journal-title":"Hepatology"},{"key":"2021113010340735500_B54","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1038\/sj.onc.1209556","article-title":"Dysregulation of growth factor signaling in human hepatocellular carcinoma","volume":"25","author":"Breuhahn","year":"2006","journal-title":"Oncogene"},{"key":"2021113010340735500_B55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1476-4598-11-85","article-title":"Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells","volume":"11","author":"Grabinski","year":"2012","journal-title":"Mol. Cancer"},{"key":"2021113010340735500_B56","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1054\/bjoc.2000.1580","article-title":"Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma","volume":"84","author":"Ito","year":"2001","journal-title":"Br. J. Cancer"},{"key":"2021113010340735500_B57","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"2021113010340735500_B58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/hep.26662","article-title":"MicroRNA-494 within an oncogenic microRNA megacluster regulates G1\/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer","volume":"59","author":"Lim","year":"2014","journal-title":"Hepatology"},{"key":"2021113010340735500_B59","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3892\/or_00000682","article-title":"High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma","volume":"23","author":"Chung","year":"2010","journal-title":"Oncol. Rep."},{"key":"2021113010340735500_B60","doi-asserted-by":"publisher","first-page":"e37188","DOI":"10.1371\/journal.pone.0037188","article-title":"Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS One"},{"key":"2021113010340735500_B61","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbrc.2010.10.130","article-title":"miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines","volume":"403","author":"Henry","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113010340735500_B62","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1158\/0008-5472.CAN-10-0145","article-title":"MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells","volume":"70","author":"Fornari","year":"2010","journal-title":"Cancer Res."},{"key":"2021113010340735500_B63","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/j.1440-1746.2011.06758.x","article-title":"Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1alpha in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients","volume":"26","author":"Wang","year":"2011","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/128\/1\/29\/446107\/cs1280029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/128\/1\/29\/446107\/cs1280029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T13:08:29Z","timestamp":1746277709000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/128\/1\/29\/70842\/Feasibility-of-global-miRNA-analysis-from-fine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,27]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20140007","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"type":"print","value":"0143-5221"},{"type":"electronic","value":"1470-8736"}],"subject":[],"published":{"date-parts":[[2014,8,27]]}}}